

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Company

2021/03/05 22:00:01



Price
64.62
USD

Difference ▲
2.20%(1.39)



Contact Details

GILEAD SCIENCES, INC. Tel: 1-650-574-3000
 -- Fax: 1-650-578-9264
 333 Lakeside Drive Web: <http://www.gilead.com>
 94404 Foster City E-mail: -

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	15,996,000,000		30,296,000,000		35,836,000,000	
Common stock capital		-		1,000,000		1,000,000
Fixed assets	52,411,000,000		31,331,000,000		27,839,000,000	
Equity capital of a company		18,221,000,000		22,650,000,000		21,534,000,000
Cash and cash equivalents	5,997,000,000		11,631,000,000		17,940,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		11,397,000,000		9,759,000,000		10,605,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		38,789,000,000		29,218,000,000		31,536,000,000
Different income		-		-		-
Other liabilities		9,536,000,000		6,498,000,000		6,962,000,000
Total assets	68,407,000,000	68,407,000,000	61,627,000,000	61,627,000,000	63,675,000,000	63,675,000,000

Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	-	11,800	11,000
Equity ratio	26.66%	36.96%	34.05%
Debt-equity ratio	275.04%	170.59%	193.69%

Others

	2020	2019	2018
Tax Expense Rate	94.67%	-3.95%	29.99%

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	24,642,000,000	22,322,000,000	22,214,000,000
Net income	123,000,000	5,386,000,000	5,455,000,000
EBIT	1,381,097,500	5,093,262,500	7,344,890,000
Operating income before taxes	1,669,000,000	5,160,000,000	7,799,000,000
Cash Flow	8,168,000,000	9,144,000,000	8,400,000,000
Net interest income	-	-995,000,000	-1,077,000,000
Research and development expenses	4,857,000,000	8,306,000,000	4,198,000,000
Income taxes	1,580,000,000	-204,000,000	2,339,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	-	1,565,378	1,671,099

Board of Directors

Members of Management Board

George Shultz	Member of Board of Directors
Jacqueline Barton	Member of Board of Directors
Jeffrey Bluestone	Member of Board of Directors
John Cogan	Member of Board of Directors
Richard Whitley	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Anthony Welters	Member of Board of Directors
Gayle Wilson	Member of Board of Directors
Harish M. Manwani	Member of Board of Directors
Javier Rodriguez	Member of Board of Directors
Kelly Kramer	Member of Board of Directors
Kevin Lofton	Member of Board of Directors
Per Wold-Olsen	Member of Board of Directors
Daniel O'Day	Chairman of Managing Board
Douglas Maffei	Member of Executive Committee
Linda Higgins	Member of Executive Committee
Mark Genovese	Member of Executive Committee
Merdad Parsey	Member of Executive Committee
Michael Quigley	Member of Executive Committee
Tomas Cihlar	Member of Executive Committee